The earnings call reflects a strong overall performance with significant revenue growth, successful product launches, and positive pipeline developments. However, challenges in patient identification and pricing strategy, along with uncertainties in data outcomes, present areas of concern.

Company Guidance -

Q3 2025

During the Ionis Second Quarter 2025 Financial Results Conference Call, the company provided updated financial guidance for 2025, driven by the successful early commercial performance of Tryngolza, their first independent launch. Tryngolza, the FDA-approved treatment for familial chylomicronemia syndrome, achieved $19 million in net product sales for the second quarter, a threefold increase from the previous quarter. This strong performance contributed to Ionis raising its 2025 revenue guidance by $100 million to a range of $850 million. The company also expects to generate $75 million to $80 million in Tryngolza sales for the year. Additionally, Ionis is preparing for the potential FDA approval and launch of Donidalorsen for hereditary angioedema, with an anticipated approval date of August 21. The company projects an operating loss between $300 million and $325 million and aims to end the year with a cash balance of approximately $2 billion. Overall, Ionis is well-positioned for continued growth, with multiple product launches and a robust late-stage pipeline.

Strong Commercial Launch of Tryngolza

Tryngolza reported $19 million in net product sales for Q2, a threefold increase from the previous quarter, exceeding revenue expectations and highlighting strong execution and unmet need.

Increased 2025 Financial Guidance

Ionis increased its 2025 revenue guidance by $100 million, projecting $850 million in revenue due to strong performance and early success of Tryngolza.

Pipeline Progress and Potential Approvals

Anticipation of FDA approval for Donidalorsen by August 21, with positive momentum for Olezarsen and Zilganersen, indicating substantial future revenue potential.

Substantial Revenue Growth

Revenue for Q2 reached $452 million, a twofold increase year-over-year, driven by substantial R&D collaboration revenue and strong commercial product performance.

Positive Feedback for Tryngolza

High physician and patient satisfaction with Tryngolza, supported by favorable payer dynamics and 90% of patients having $0 out-of-pocket costs.

Ionis Pharmaceuticals (IONS) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

IONS Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 30, 2025	2025 (Q3)	-1.20 / -	-0.95	―	―	―
Jul 30, 2025	2025 (Q2)	-0.09 / 0.70	-0.45	255.56% (+1.15)
Apr 30, 2025	2025 (Q1)	-1.10 / -0.93	-0.98	5.10% (+0.05)
Feb 19, 2025	2024 (Q4)	-1.12 / -0.66	-0.06	-1000.00% (-0.60)
Nov 06, 2024	2024 (Q3)	-1.14 / -0.95	-1.03	7.77% (+0.08)
Aug 01, 2024	2024 (Q2)	-0.94 / -0.45	-0.6	25.00% (+0.15)
May 07, 2024	2024 (Q1)	-1.05 / -0.98	-0.87	-12.64% (-0.11)
Feb 21, 2024	2023 (Q4)	-0.80 / -0.06	-0.37	83.78% (+0.31)
Nov 02, 2023	2023 (Q3)	-1.01 / -1.03	-0.33	-212.12% (-0.70)
Aug 09, 2023	2023 (Q2)	-0.88 / -0.60	-0.74	18.92% (+0.14)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

IONS Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jul 30, 2025	$41.48	$43.37	+4.56%
Apr 30, 2025	$29.81	$30.71	+3.02%
Feb 19, 2025	$31.95	$31.81	-0.44%
Nov 06, 2024	$38.80	$39.04	+0.62%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Ionis Pharmaceuticals Inc. (IONS) report earnings?

Ionis Pharmaceuticals Inc. (IONS) is schdueled to report earning on Oct 30, 2025, Before Open (Confirmed).

What is Ionis Pharmaceuticals Inc. (IONS) earnings time?

Ionis Pharmaceuticals Inc. (IONS) earnings time is at Oct 30, 2025, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is IONS EPS forecast?

IONS EPS forecast for the fiscal quarter 2025 (Q3) is -1.2.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing